Dapansutrile

Dapansutrile

SCHEMBL9934796

CS(=O)(=O)CCC#N

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NLRP3

The experimentally established mechanism targets of Dapansutrile. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dapansutrile SCHEMBL9935165 0.97
SCHEMBL14325274 0.83
Dapansutrile SCHEMBL20528619 0.81
SCHEMBL31390822 0.81 NLRP3 (0.68)
SCHEMBL21616866 0.79 NLRP3 (0.65)
SCHEMBL18660481 0.79 NLRP3 (0.65)
SCHEMBL18660477 0.79 NLRP3 (0.65)
SCHEMBL21616867 0.79 NLRP3 (0.65)
SCHEMBL9428536 0.79
Dapansutrile SCHEMBL11291946 0.77 NLRP3 (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099526-A1 COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) 2026-05-15 WO claimed
US-20260091162-A1 SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY KULKARNI ASHISH (US) 2026-04-02 US claimed
US-12582628-B2 Methods for treating breast cancer OLATEC THERAPEUTICS, INC. (US) 2026-03-24 US claimed
US-12569463-B2 Method for treating diabetes OLATEC THERAPEUTICS, INC. (US) 2026-03-10 US claimed
EP-4701663-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-03-04 EP claimed
US-20250375534-A1 COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS BioNTech SE (DE) 2025-12-11 US claimed
US-20250364144-A1 CANCER PHARMACOPREVENTION THROUGH ARTIFICIAL INTELLIGENCE UNIV ILLINOIS (US) 2025-11-27 US claimed
EP-3768384-B1 METHODS FOR TREATING MELANOMA OLATEC THERAPEUTICS INC (US) 2025-06-25 EP claimed
US-20250177565-A1 METHODS AND MATERIALS FOR INHIBITING/PREVENTING THE TRAFFICKING OF MONOCYTES TO THE CENTRAL NERVOUS SYSTEM DARTMOUTH COLLEGE (US) 2025-06-05 US claimed
US-12318361-B2 Methods for treating cardiovascular diseases OLATEC THERAPEUTICS, INC. (US) 2025-06-03 US claimed
US-8802885-B2 Process for preparing 3-methylsulfonylpropionitrile OLATEC INDUSTRIES LLC (US) 2014-08-12 US claimed
WO-2013184586-A1 METHOD FOR TREATING SKIN INFLAMMATORY DISEASES OLATEC INDUSTRIES LLC (US) 2013-12-12 WO claimed
EP-2651407-A2 3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN Olatec Industries LLC (US) 2013-10-23 EP claimed
WO-2013130436-A1 PROCESS FOR PREPARING 3-METHYLSULFONYLPROPIONITRILE OLATEC INDUSTRIES LLC. (US) 2013-09-06 WO claimed
US-20130225865-A1 PROCESS FOR PREPARING 3-METHYLSULFONYLPROPIONITRILE OLATEC INDUSTRIES LLC (US) 2013-08-29 US claimed
CN-103260613-A 3-methanesulfonylpropionitrile for treating inflammation and pain OLATEC IND LLC 2013-08-21 CN claimed
US-20130172410-A1 3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN OLATEC INDUSTRIES LLC (US) 2013-07-04 US claimed
US-8476316-B2 3-methanesulfonylpropionitrile for treating inflammation and pain OLATEC INDUSTRIES LLC (US) 2013-07-02 US claimed
US-20120157524-A1 3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN OLATEC THERAPEUTICS, INC. 2012-06-21 US claimed
WO-2012082718-A2 3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN OLATEC INDUSTRIES LLC (US) 2012-06-21 WO claimed